These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38299143)

  • 21. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.
    Karlsson MJ; Costa Svedman F; Tebani A; Kotol D; Höiom V; Fagerberg L; Edfors F; Uhlén M; Egyhazi Brage S; Maddalo G
    Cancer Res; 2021 May; 81(9):2545-2555. PubMed ID: 33574091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considering adjuvant therapy for stage II melanoma.
    Poklepovic AS; Luke JJ
    Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
    Davar D; Tarhini AA; Kirkwood JM
    Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.
    Sun W; Xu Y; Yan W; Wang C; Hu T; Luo Z; Zhang X; Liu X; Chen Y
    Cancer Med; 2023 Aug; 12(15):15945-15954. PubMed ID: 37403699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients.
    Jia DD; Li T
    Sci Rep; 2024 Jul; 14(1):16607. PubMed ID: 39025927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.
    Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R
    Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma.
    Ladányi A; Papp E; Mohos A; Balatoni T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Ferrone S
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
    Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
    J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
    Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
    Front Immunol; 2022; 13():894110. PubMed ID: 35967450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
    Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
    Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center.
    Kurzhals JK; Klee G; Hagelstein V; Zillikens D; Terheyden P; Langan EA
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
    Lim SY; da Silva IP; Adegoke NA; Lo SN; Menzies AM; Carlino MS; Scolyer RA; Long GV; Lee JH; Rizos H
    Mol Cancer; 2024 Oct; 23(1):228. PubMed ID: 39394099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma.
    Boutros C; Belkadi-Sadou D; Marchand A; Roy S; Routier E; Robert C
    Curr Oncol Rep; 2023 Sep; 25(9):989-996. PubMed ID: 37266890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8
    Wang Z; Peng M
    Sci Rep; 2021 Apr; 11(1):9164. PubMed ID: 33911146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.